Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Learn
Share
Network
Benefit
Delivering Affordable Innovation Through Global Partnerships
Head, Global Clinical Operations
Novartis
Badhri Srinivasan has been Head, Global Clinical Operations, Novartis, since August 2016. He is a member of the Global Leadership Team of Novartis (GLT) and a member of the Innovation Management Board (IMB) of Novartis.
Badhri Srinivasan joined Novartis in August, 2016. Before joining Novartis, Badhri Srinivasan was CEO and co-founder of Remarque Systems, a technology company that develops state-of-the art disruptive technology solutions for the life sciences industry.
Prior to Remarque Systems, Badhri was Senior Vice President and Head, Global Delivery Network and Global Data and Safety Monitoring at Quintiles. In this role, he led a team of >5,000 associates located across Asia Pacific, South Africa, Europe and North America to deliver best-in-class customer service and flexible offerings through industry-leading processes, automation, analytics and information management.
Earlier, he was Vice President of Enterprise Analytics and Business Process Management in Quintiles Innovation and Head of the Enterprise Transformation Unit (ETU), a group dedicated to strategizing efficient clinical trial execution. Additionally, he led a partnership with Harvard/MIT’s new drug development paradigm (NEWDIGGS) initiative in Singapore.
Badhri has been working in clinical trial design and execution for more than 25 years and has helped many of the top Pharmaceutical companies with drug development strategy, including strategies for dose selection, combination Phase II/III designs, sample size re-estimation and group sequential methods. Badhri is a member of multiple scientific, academic and executive advisory committees. He has represented numerous pharmaceutical companies at the Food and Drug Administration, European Medicines Agency and Medicines and Healthcare products Regulatory Agency.
Badhri was named to PharmaVOICE 100, PharmaVOICE magazine’s list of the 100 most inspiring people in the life-sciences industry.
In addition to clinical trial operations and process re-engineering, his work has involved development of mathematical algorithms to reduce cost and speed assets through clinic as well as new models of clinical development. He has patents pending on several of his algorithms.
Badhri’s formal training is in Mathematical Statistics and Biostatistics. He holds an ABD in Biostatistics from the University of North Carolina, Chapel Hill, and an MS in Mathematical Statistics from Bangalore University, India.
Badhri Srinivasan has been Head, Global Clinical Operations, Novartis, since August 2016. He is a member of the Global Leadership Team of Novartis (GLT) and a member of the Innovation Management Board (IMB) of Novartis.
Badhri Srinivasan joined Novartis in August, 2016. Before joining Novartis, Badhri Srinivasan was CEO and co-founder of Remarque Systems, a technology company that develops state-of-the art disruptive technology solutions for the life sciences industry.
Prior to Remarque Systems, Badhri was Senior Vice President and Head, Global Delivery Network and Global Data and Safety Monitoring at Quintiles. In this role, he led a team of >5,000 associates located across Asia Pacific, South Africa, Europe and North America to deliver best-in-class customer service and flexible offerings through industry-leading processes, automation, analytics and information management.
Earlier, he was Vice President of Enterprise Analytics and Business Process Management in Quintiles Innovation and Head of the Enterprise Transformation Unit (ETU), a group dedicated to strategizing efficient clinical trial execution. Additionally, he led a partnership with Harvard/MIT’s new drug development paradigm (NEWDIGGS) initiative in Singapore.
Badhri has been working in clinical trial design and execution for more than 25 years and has helped many of the top Pharmaceutical companies with drug development strategy, including strategies for dose selection, combination Phase II/III designs, sample size re-estimation and group sequential methods. Badhri is a member of multiple scientific, academic and executive advisory committees. He has represented numerous pharmaceutical companies at the Food and Drug Administration, European Medicines Agency and Medicines and Healthcare products Regulatory Agency.
Badhri was named to PharmaVOICE 100, PharmaVOICE magazine’s list of the 100 most inspiring people in the life-sciences industry.
In addition to clinical trial operations and process re-engineering, his work has involved development of mathematical algorithms to reduce cost and speed assets through clinic as well as new models of clinical development. He has patents pending on several of his algorithms.
Badhri’s formal training is in Mathematical Statistics and Biostatistics. He holds an ABD in Biostatistics from the University of North Carolina, Chapel Hill, and an MS in Mathematical Statistics from Bangalore University, India.